ConductScience.org, home

Paper21079147

Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study.

Okamoto I and 19 others. J Clin Oncol, 2010. Cited by 150 papers, by iCite.

Cite this record

ConductScience Library. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. Papers, record 21079147. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/21079147

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study.
PubMed
Journal
J Clin Oncol
PubMed
Year
2010
PubMed
Publication types
Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial
PubMed
Citations, by iCite
150
iCite
Relative citation ratio, by iCite
3.39
iCite
Revised in PubMed
2022-04-08
PubMed

Authors20

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Okamoto IIsamu
2Yoshioka HHiroshige
3Morita SSatoshi
4Ando MMasahiko
5Takeda KKoji
6Seto TTakashi
7Yamamoto NNobuyuki
8Saka HHideo
9Asami KKazuhiro
10Hirashima TTomonori
11Kudoh SShinzoh
12Satouchi MMiyako
13Ikeda NNorihiko
14Iwamoto YYasuo
15Sawa TToshiyuki
16Miyazaki MMasaki
17Tamura KKenji
18Kurata TTakayasu
19Fukuoka MMasahiro
20Nakagawa KKazuhiko

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Carcinoma, Non-Small-Cell LungMajor topic
Lung NeoplasmsMajor topic
Administration, Oral
Adult
Aged
Carboplatin
Drug Combinations
Female
Humans
Male
Middle Aged
Oxonic Acid
Paclitaxel
Survival Analysis
Tegafur

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT01874678A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung CancerBackground

Source ClinicalTrials.gov

Download CSV of trials

Cited by75

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 150 citations.

PMIDTitleJournalYearIn PapersSource
42032207Incidence and risk factors related to ocular adverse effects caused by S-1 chemotherapy.Jpn J Ophthalmol2026https://conductscience.org/library/papers/42032207PubMed
39035725Docetaxel plus S-1 versus docetaxel plus capecitabine as first-line treatment for advanced breast cancer patients: a prospective randomized phase II study.J Natl Cancer Cent2023https://conductscience.org/library/papers/39035725PubMed
38146645Potential of fluoropyrimidine to be an immunologically optimal partner of immune checkpoint inhibitors through inducing immunogenic cell death for thoracic malignancies.Thorac Cancer2024https://conductscience.org/library/papers/38146645PubMed
37589158Phase II trial of daily S-1 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan lung cancer group 1101.Thorac Cancer2023https://conductscience.org/library/papers/37589158PubMed
37157831Patients with Lower Positive Lymph Nodes Ratio May Benefit from Preoperative Radiotherapy in Stage III Non-Small Cell Lung Cancer.Technol Cancer Res Treat2023https://conductscience.org/library/papers/37157831PubMed
36961615Lineage of drug discovery research on fluorinated pyrimidines: chronicle of the achievements accomplished by Professor Setsuro Fujii.Int J Clin Oncol2023https://conductscience.org/library/papers/36961615PubMed
36285504S-1 eliminates MDSCs and enhances the efficacy of PD-1 blockade via regulation of tumor-derived Bv8 and S100A8 in thoracic tumor.Cancer Sci2023https://conductscience.org/library/papers/36285504PubMed
35782342Chemotherapy for patients with advanced lung cancer with interstitial lung disease: a prospective observational study.Ther Adv Chronic Dis2022https://conductscience.org/library/papers/35782342PubMed
35000608Concurrent chemoradiotherapy with cisplatin + S-1 versus cisplatin + other third-generation agents for locally advanced non-small-cell lung cancer: a meta-analysis of individual participant data.BMC Pulm Med2022https://conductscience.org/library/papers/35000608PubMed
34916713S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model.Nagoya J Med Sci2021https://conductscience.org/library/papers/34916713PubMed
33738585Role of surgery in a novel multimodal therapeutic approach to complete cure of advanced lung cancer: current and future perspectives.Surg Today2022https://conductscience.org/library/papers/33738585PubMed
33328765Anlotinib Plus S-1 for Patients with EGFR Mutation-Negative Advanced Squamous Cell Lung Cancer with PS Scores of 2-3 After Progression of Second-Line or Later-Line Treatment.Cancer Manag Res2020https://conductscience.org/library/papers/33328765PubMed
33159605Phase II study of the combination of S-1 with bevacizumab for patients with previously treated advanced non-squamous non-small-cell lung cancer.Int J Clin Oncol2021https://conductscience.org/library/papers/33159605PubMed
32996023Phase II trial of combination treatment with S-1/cetuximab in patients with platinum-ineligible recurrent and/or metastatic squamous cell carcinoma of the head and neck.Int J Clin Oncol2021https://conductscience.org/library/papers/32996023PubMed
32961037Characteristics of surgically resected non-small cell lung cancer patients with post-recurrence cure.Thorac Cancer2020https://conductscience.org/library/papers/32961037PubMed
32567031Bcl-2/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in pancreatic cancer cells via inhibition of Bcl-xL but not Bcl-2.Mol Cell Biochem2020https://conductscience.org/library/papers/32567031PubMed
32426292Oral Chemotherapy for Treatment of Lung Cancer.Front Oncol2020https://conductscience.org/library/papers/32426292PubMed
32351044A pilot study of adjuvant chemotherapy with carboplatin and oral S-1 for patients with completely resected stage II to IIIA non-small cell lung cancer.Thorac Cancer2020https://conductscience.org/library/papers/32351044PubMed
32060768A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer -TCOG 1101.Int J Clin Oncol2020https://conductscience.org/library/papers/32060768PubMed
31619197Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer.BMC Cancer2019https://conductscience.org/library/papers/31619197PubMed

See all 75 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/21079147

GET https://conductscience.org/api/papers/v1/21079147/cited_by?page=2